Two Sigma Investments LP reduced its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 71.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 80,863 shares of the company's stock after selling 199,902 shares during the quarter. Two Sigma Investments LP owned about 0.08% of Biohaven worth $3,020,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in BHVN. Spire Wealth Management acquired a new position in Biohaven in the fourth quarter valued at about $56,000. Amalgamated Bank raised its position in shares of Biohaven by 21.9% in the 4th quarter. Amalgamated Bank now owns 2,929 shares of the company's stock valued at $109,000 after acquiring an additional 527 shares during the period. US Bancorp DE boosted its stake in Biohaven by 36.7% during the 4th quarter. US Bancorp DE now owns 2,971 shares of the company's stock worth $111,000 after acquiring an additional 798 shares during the last quarter. Quarry LP acquired a new position in Biohaven during the fourth quarter valued at approximately $112,000. Finally, Lazard Asset Management LLC grew its holdings in Biohaven by 47.4% during the fourth quarter. Lazard Asset Management LLC now owns 3,207 shares of the company's stock valued at $119,000 after purchasing an additional 1,031 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on shares of Biohaven and gave the stock a "buy" rating in a report on Thursday, March 20th. JPMorgan Chase & Co. lowered their target price on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Finally, William Blair raised Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Biohaven has a consensus rating of "Buy" and an average target price of $59.46.
Read Our Latest Report on Biohaven
Biohaven Trading Up 0.4%
NYSE:BHVN traded up $0.06 on Wednesday, hitting $15.84. The company's stock had a trading volume of 183,975 shares, compared to its average volume of 1,227,280. Biohaven Ltd. has a one year low of $14.33 and a one year high of $55.70. The stock has a fifty day moving average of $19.04 and a two-hundred day moving average of $31.28. The firm has a market capitalization of $1.62 billion, a P/E ratio of -1.69 and a beta of 1.18.
Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.50). As a group, sell-side analysts anticipate that Biohaven Ltd. will post -8.9 EPS for the current year.
Biohaven Profile
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
See Also
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
